USD
$0.00
(0.00%
)At Close (As of Sep 8, 2025)
$1.30B
Market Cap
-
P/E Ratio
-0.41
EPS
$5.22
52 Week High
$0.65
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$342K |
Total Revenue | $3.9M |
Cost Of Revenue | $4.3M |
Costof Goods And Services Sold | $4.3M |
Operating Income | -$135M |
Selling General And Administrative | $41M |
Research And Development | $53M |
Operating Expenses | $135M |
Investment Income Net | - |
Net Interest Income | $1.4M |
Interest Income | $1.4M |
Interest Expense | $6K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $4.5M |
Income Before Tax | -$128M |
Income Tax Expense | -$1.8M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$126M |
Comprehensive Income Net Of Tax | - |
Ebit | -$128M |
Ebitda | -$123M |
Net Income | -$126M |
Field | Value (USD) |
---|---|
Total Assets | $145M |
Total Current Assets | $102M |
Cash And Cash Equivalents At Carrying Value | $30M |
Cash And Short Term Investments | $30M |
Inventory | - |
Current Net Receivables | $1.2M |
Total Non Current Assets | $43M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $4.5M |
Intangible Assets Excluding Goodwill | $4.5M |
Goodwill | $19M |
Investments | - |
Long Term Investments | - |
Short Term Investments | $68M |
Other Current Assets | $3.3M |
Other Non Current Assets | - |
Total Liabilities | $107M |
Total Current Liabilities | $22M |
Current Accounts Payable | $3.5M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1.9M |
Total Non Current Liabilities | $58M |
Capital Lease Obligations | $5.5M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $5.5M |
Other Current Liabilities | $15M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $67M |
Treasury Stock | - |
Retained Earnings | -$2.1B |
Common Stock | - |
Common Stock Shares Outstanding | $268M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$68M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $4.5M |
Capital Expenditures | $8.6M |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$21M |
Cashflow From Financing | $111M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$126M |
Field | Value (USD) |
---|---|
Gross Profit | -$342K |
Total Revenue | $3.9M |
Cost Of Revenue | $4.3M |
Costof Goods And Services Sold | $4.3M |
Operating Income | -$135M |
Selling General And Administrative | $41M |
Research And Development | $53M |
Operating Expenses | $135M |
Investment Income Net | - |
Net Interest Income | $1.4M |
Interest Income | $1.4M |
Interest Expense | $6K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $4.5M |
Income Before Tax | -$128M |
Income Tax Expense | -$1.8M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$126M |
Comprehensive Income Net Of Tax | - |
Ebit | -$128M |
Ebitda | -$123M |
Net Income | -$126M |
Field | Value |
---|---|
Ex Dividend Date | 2017-01-19 |
Declaration Date | None |
Record Date | None |
Payment Date | None |
Amount | 0.240386 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.